IDEXX Laboratories, Inc.
HealthcareNASDAQ:IDXX · NASDAQ Global Select
+$1.46 today
Vol 0.23M · Avg 0.58M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $200.5M |
| Receivables | $603.5M |
| Inventory | $382.4M |
| Other Current | $267.6M |
| Total Current Assets | $1.5B |
| PP&E (Net) | $740.4M |
| Goodwill | $412.1M |
| Intangible Assets | $104.8M |
| Other Non-current | $674.2M |
| Total Non-current Assets | $1.9B |
| Total Assets | $3.4B |
Analysis
Selected assets total $3.4B for Latest. The largest visible component is PP&E (Net) at $740.4M, about 21.9% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $180.1M -37.5% | $288.3M -36.5% | $453.9M +303.3% | $112.5M -22.1% | $144.5M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $0 | $0 | $0 | $0 | $0 | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $693.2M +23.5% | $561.3M +6.0% | $529.5M +7.9% | $490.9M +15.3% | $425.6M | $533.8M | $399.4M | -$1.7B |
| Inventory | $377.8M -1.1% | $381.9M +0.4% | $380.3M +3.4% | $367.8M +36.7% | $269.0M | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $31.3M -71.5% | $109.8M +32.1% | $83.1M -6.0% | $88.5M +18.6% | $74.6M | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $1.3B -4.3% | $1.4B -6.4% | $1.5B +35.7% | $1.1B +15.3% | $955.7M | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $870.6M +5.0% | $829.3M +1.4% | $817.7M +6.5% | $768.1M +10.9% | $692.8M | $1.2B | $1.5B | $687.8M |
| Goodwill | $414.0M +2.2% | $405.1M +10.7% | $366.0M +1.2% | $361.8M +0.7% | $359.3M | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $109.8M -1.6% | $111.7M +32.2% | $84.5M -13.5% | $97.7M -1.4% | $99.0M | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $297.1M +414.7% | $57.7M +2.7% | $56.2M +1.2% | $55.5M +198.4% | $18.6M | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $27.9M -77.8% | $125.6M +17.0% | $107.4M +94.4% | $55.2M +122.8% | $24.8M | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $291.1M -20.1% | $364.2M +9.4% | $333.0M +8.5% | $307.0M +7.0% | $287.0M | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $2.0B +6.2% | $1.9B +7.3% | $1.8B +7.3% | $1.6B +11.1% | $1.5B | -$15.3B | $14.8B | $11.3B |
| Total Assets | $3.4B +1.7% | $3.3B +1.0% | $3.3B +18.7% | $2.7B +12.7% | $2.4B | $13.3B | $11.9B | $10.6B |
| Account Payables | $110.4M -3.3% | $114.2M +3.2% | $110.6M +0.4% | $110.2M -5.1% | $116.1M | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $500.1M +19.7% | $417.8M +28.6% | $325.0M -50.3% | $654.0M +340.4% | $148.5M | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 -100.0% | $62.3M -28.1% | $86.6M +78.3% | $48.5M +13.9% | $42.6M | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $35.3M +4.3% | $33.8M -9.1% | $37.2M -2.0% | $37.9M -5.2% | $40.0M | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $202.0M +15.7% | $174.6M +0.1% | $174.4M +21.9% | $143.0M -21.8% | $182.9M | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $1.1B +7.6% | $1.1B +12.2% | $951.5M -23.0% | $1.2B +61.8% | $763.6M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $476.0M +5.8% | $449.8M -27.8% | $622.9M -10.3% | $694.4M -10.4% | $775.2M | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $31.9M +181.7% | $11.3M +56.4% | $7.2M -11.2% | $8.2M -8.8% | $8.9M | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $32.2M +19.4% | $26.9M -5.6% | $28.5M -7.5% | $30.9M -25.0% | $41.2M | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | -$44.6M -200.6% | $44.3M -32.3% | $65.5M -3.0% | $67.6M -4.7% | $70.9M | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $596.6M -5.3% | $630.2M -23.5% | $823.8M -8.7% | $902.2M -8.3% | $983.6M | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $1.7B +2.8% | $1.7B -4.4% | $1.8B -17.0% | $2.1B +22.4% | $1.7B | $14.7B | $3.7B | $9.6B |
| Common Stock | $10.8M +0.5% | $10.8M +0.3% | $10.8M +0.3% | $10.7M +0.3% | $10.7M | $651.4M | $517.0M | $382.6M |
| Retained Earnings | $6.4B +19.9% | $5.3B +20.0% | $4.4B +23.5% | $3.6B +23.3% | $2.9B | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | -$62.8M +33.0% | -$93.6M -31.5% | -$71.2M +8.5% | -$77.8M -45.5% | -$53.5M | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 -100.0% | $5.9M +6.4% | $5.5M +6.7% | $5.2M -9.4% | $5.7M | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | $1.6B +0.6% | $1.6B +7.5% | $1.5B +143.9% | $608.7M -11.8% | $690.0M | $9.1B | $7.7B | $3.3B |
| Total Debt | $1.1B +9.1% | $986.9M -7.5% | $1.1B -27.4% | $1.5B +42.6% | $1.0B | $724.2M | $410.6M | $399.4M |
| Net Debt | $897.1M +28.4% | $698.7M +13.9% | $613.4M -54.8% | $1.4B +53.1% | $886.6M | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
argenx SE
NASDAQ:ARGX
$55.60B
Cencora, Inc.
NYSE:COR
$54.90B
Becton, Dickinson and Company
NYSE:BDX
$52.82B
Cardinal Health, Inc.
NYSE:CAH
$52.34B
Edwards Lifesciences Corporation
NYSE:EW
$48.80B
Alnylam Pharmaceuticals, Inc.
NASDAQ:ALNY
$37.89B
Agilent Technologies, Inc.
NYSE:A
$36.54B
Zoetis Inc.
NYSE:ZTS
$33.66B
IQVIA Holdings Inc.
NYSE:IQV
$29.85B
Veeva Systems Inc.
NYSE:VEEV
$25.83B
SEC Filings
Recent regulatory filings
No filings found.
How much cash does IDXX have?
IDEXX Laboratories, Inc. (IDXX) reported $180.07M in cash and equivalents in fiscal 2025.
How much debt does IDXX carry?
IDEXX Laboratories, Inc. (IDXX) reported $1.08B of total debt, with net debt of $897.14M.
Explore More
Continue the stock analysis
Jump to another research area for this company.